<DOC>
	<DOCNO>NCT00800345</DOCNO>
	<brief_summary>This Phase 1 , dose-escalation study female patient recurrent persistent gynecologic tumor .</brief_summary>
	<brief_title>Phase I Trial Oral Metronomic Topotecan Oral Pazopanib Treat Recurrent/Persistent Gynecologic Tumors</brief_title>
	<detailed_description>This Phase 1 , dose-escalation study female patient recurrent persistent gynecologic tumor . The study include Screening Phase , Treatment Phase Followup Phase . In Screening Phase subject 's eligibility study participation determine ; phase last 28 day . The Treatment Phase begin subject start study treatment continue subject remove study treatment . The Follow-up Phase last 30 day subject end study treatment . The study conduct approximately 1 site . Treatment cycle length 28 day . Radiologic image repeat every 2 cycle treatment .</detailed_description>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Subjects must provide write informed consent prior performance study specific procedure , must willing comply treatment followup . Female patient , great 18 year age histologically confirm recurrent/persistent gynecologic malignancy . For patient recurrent/persistent epithelial ovarian , fallopian tube , primary peritoneal carcinoma : persistent disease = progression primary platinum therapy ; recurrent disease = disease recur ≤ 12 month discontinue primary platinum therapy ; disease recurrence occur &gt; 12 month discontinue primary platinum therapy , must progression either 2nd platinum therapy &lt; 6 month discontinue 2nd platinum therapy . For patient gynecologic malignancy : Malignancy metastatic unresectable curative palliative measure exist longer effective . Maximum two total prior treatment ( include neoadjuvant , adjuvant , metastatic setting ) recurrent persistent gynecologic tumor include chemotherapy , hormonal therapy , investigational therapy , radiation therapy , etc . ) Disease may measurable nonmeasurable accord RECIST version 1.0 Gynecologic Oncology Group ( GOG ) performance status 0,1 , 2 Must life expectancy least six month Adequate bone marrow , liver , renal , cardiac function study entry assess follow : Hemoglobin &gt; 9.0 g/dL . Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L . Platelet count ≥ 100 x 10^9/L . Prothrombin time ( PT ) international normalize ratio ( INR ) &lt; 1.2 x upper limit normal ( ULN ) . Partial thromboplastin time ( PTT ) &lt; 1.2 x ULN . Total bilirubin ≤ 1.5 x ULN . Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN . Creatinine ≤ 1.5 mg/dL serum creatinine great 1.5 mg/dL , calculate creatinine clearance must &gt; 50 mL/min Urine dipstick protein &lt; 2+ urine protein creatinine ( UPC ) ratio &lt; 1.0 . Left ventricular ejection fraction ( LVEF ) ≥ 50 % institutional low limit normal ( LLN ) Patients must physiologically incapable become pregnant , postmenopausal , negative pregnancy test agree use adequate contraception . Treatment naive patient . Repetitive prolong neutropenia thrombocytopenia previous therapy . Concurrent malignancy malignancy study . Subjects another malignancy disease free 3 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . Prior radiation therapy . Myelosuppressive chemotherapy within past 28 day recover myelosuppressive effect recent chemotherapy . Use investigational agent , include investigational anticancer agent , immunotherapy , biological therapy , hormonal therapy within 28 day prior first dose study treatment . Prior major surgery trauma within 28 day prior first dose study treatment and/or presence nonhealing wound , fracture , ulcer . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis . Inability swallow capsule clinically significant gastrointestinal abnormality include , limited : Malabsorption syndrome Major resection stomach small bowel could affect absorption study treatment Active peptic ulcer disease Inflammatory bowel disease Ulcerative colitis , gastrointestinal condition increase risk perforation History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day prior begin study treatment . Unresolved bowel obstruction diarrhea ≥ Grade 1 Known intraluminal metastatic lesion ( ) risk bleed Known endobronchial lesion involvement large pulmonary vessel tumor . Presence uncontrolled infection . Prolongation correct QT interval &gt; 480 millisecond . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) Poorly control hypertension ( define systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg ) . Initiation adjustment antihypertensive medication ( ) permit prior study entry . History cerebrovascular accident , transient ischemic attack , pulmonary embolism , insufficiently treat deep vein thrombosis ( DVT ) within past 6 month . Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible Evidence active bleeding bleed diathesis . Recent hemoptysis excess 2.5 mL within 8 week 1st dose study treatment . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Use prohibit medication within 14 day 5 halflives drug ( whichever longer ) prior first dose study treatment study . Prior use investigational license antiangiogenic agent , include topotecan , bevacizumab , thalidomide , agent target vascular endothelial growth factor ( VEGF ) , VEGF receptor , plateletderived growth factor ( PDGF ) . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia . Known hypersensitivity topoisomerase I inhibitors pazopanib . Administration nononcologic investigational drug within 30 day five halflives drug ( whichever longer ) prior first dose study treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gynecologic tumor</keyword>
</DOC>